Literature DB >> 6852443

Changes in high density lipoproteins in patients with hepatobiliary diseases. Levels and lipid composition of HDL2 and HDL3 and LCAT reaction.

G Kajiyama, K Takata, I Horiuchi, M Nakagawa, M Yamamoto, A Miyoshi.   

Abstract

Lipids of HDL (high density lipoproteins) and their subfractions (HDL2 and HDL3), and LCAT activity (lecithin: cholesterol acyltransferase) were determined in hepatobiliary diseases without severe hyperbilirubinemia (less than 10 mg/dl). The decrease in major lipid constituents (cholesterol and phospholipids) of HDL was mainly attributable to the decrease in those of HDL3, except in some liver diseases of acute or severe stage (acute hepatitis in an acute stage and hepatoma) which were accompanied with a simultaneous moderate decrease in those of HDL2 and in fatty liver which showed a preferential decrease in those of HDL2. The LCAT activity also decreased in several diseases. Some of the hepatobiliary diseases, on the contrary, showed an increase in HDL-triglycerides (mostly in HDL3 and in some diseases also in HDL2) which might participate to some extent in secondary hyperlipidemia in the liver parenchymal diseases, although they were the minor lipid constituents of HDL. From results that HDL3- but not HDL2-cholesterol levels significantly correlated with serum total protein, albumin and choline esterase, it was suggested that the decrease in large constituents of HDL, particularly of HDL3, is caused by hepatocellular dysfunction which causes inhibition of protein and lipid syntheses in the liver in most of the hepatobiliary diseases except for fatty liver which has a preferential decrease in HDL2 lipids.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6852443

Source DB:  PubMed          Journal:  Gastroenterol Jpn        ISSN: 0435-1339


  22 in total

1.  The lipid composition of serum in patients with liver disease.

Authors:  G B PHILLIPS
Journal:  J Clin Invest       Date:  1960-11       Impact factor: 14.808

2.  THE LIPIDS OF SERUM AND LIVER IN PATIENTS WITH HEPATIC DISEASES.

Authors:  E B Man; B L Kartin; S H Durlacher; J P Peters
Journal:  J Clin Invest       Date:  1945-09       Impact factor: 14.808

3.  The relationship between serum lipids and skin xanthomata in 18 patients with primary biliary cirrhosis.

Authors:  E H AHRENS; H G KUNKEL
Journal:  J Clin Invest       Date:  1949-11       Impact factor: 14.808

4.  Apolipoprotein A-1 in cholestatic liver diseases.

Authors:  K Yamamoto; S Koga; H Ibayashi
Journal:  Clin Chim Acta       Date:  1978-07-01       Impact factor: 3.786

5.  A new colorimetric method for the determination of plasma lecithin-cholesterol acyltransferase activity.

Authors:  T Nagasaki; Y Akanuma
Journal:  Clin Chim Acta       Date:  1977-03-15       Impact factor: 3.786

6.  Determination of cholesterol and phospholipids of HDL2, HDL3 and VHDL in patients with atherosclerosis and diabetes mellitus.

Authors:  G Kajiyama; M Nakagawa; K Takata; S Nakao; A Miyoshi
Journal:  Hiroshima J Med Sci       Date:  1981-09

7.  [Study of plasma lipids in patients with liver cirrhosis and hepatitis].

Authors:  S Platzer; S Sailer; F Sandhofer; H Braunsteiner
Journal:  Wien Klin Wochenschr       Date:  1966-01-28       Impact factor: 1.704

Review 8.  Plasma lipids and lipoproteins in liver disease.

Authors:  N McIntyre
Journal:  Gut       Date:  1978-06       Impact factor: 23.059

9.  A lipoprotein characterizing obstructive jaundice. II. Isolation and partial characterization of the protein moieties of low density lipoproteins.

Authors:  D Seidel; P Alaupovic; R H Furman; W J McConathy
Journal:  J Clin Invest       Date:  1970-12       Impact factor: 14.808

10.  Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions.

Authors:  M Burstein; H R Scholnick; R Morfin
Journal:  J Lipid Res       Date:  1970-11       Impact factor: 5.922

View more
  1 in total

1.  Correlation between HDL2, HDL3 and serum ferritin levels with fatty liver and NAFLD activity score (NAS) in liver histology of organ donors.

Authors:  Saman Nikeghbalian; Rasoul Rahimi; Hamed Nikoupour; Neda Soleimani; Sina Vakili; Fatemeh Zal; Fahimeh Kaveh Baghbahadorani
Journal:  BMC Gastroenterol       Date:  2021-10-27       Impact factor: 3.067

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.